SMMT Summit Therapeutics Inc.
$15.33▲ +5.72%
Healthcare
Other
After hours
$15.34▲ +0.09%
Oct 27, 5:00 PM ET
Volume 4.73M
Avg Volume (10D) 5.07M
Key Metrics & Fundamentals
Market Cap
$12.23B
P/E Ratio
–
Div Yield
0.00%
52W Range
12.07 - 29.23
% vs 50 MA
-3.36%
% vs 200 MA
-5.34%
RSI-14
45.9
MACD Histogram
-0.1600
Beta (1Y vs SPY)
1.69
Free Cash Flow
-$142.03M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$224.75M
COGS
–
Operating Exp
$220.50M
Operating Income
-$220.50M
EBIT
-$220.50M
Pretax Income
-$215.70M
Net Income
-$215.70M
EPS (Diluted)
-0.28
Price & Volume History
Loading chart…
Recent News
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
MarketBeat · Oct 26, 2026 12:05 PM ET
Lunit and Summit to evaluate pathology platform for tumour analysis
Pharmaceutical Technology · Oct 26, 2026 7:00 AM ET
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
Business Wire · Oct 25, 2026 11:52 AM ET
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
PR Newswire · Oct 23, 2026 9:26 PM ET
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Business Wire · Oct 23, 2026 4:37 PM ET
U.S. Treasury Wants to Rein In Deals for Chinese Biotech and AI
Barrons.com · Oct 23, 2026 12:52 PM ET
Summit Expands Ivonescimab Development Into Biliary Tract Cancer
Zacks · Oct 22, 2026 9:49 AM ET
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
Business Wire · Oct 22, 2026 6:00 AM ET
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
Zacks · Oct 21, 2026 10:00 AM ET
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
PR Newswire · Oct 21, 2026 8:42 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SMMT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.